Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Investigate the Prevalence of Children Asthma in China

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01319292
Recruitment Status : Completed
First Posted : March 21, 2011
Last Update Posted : August 4, 2014
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Chen Yuzhi, Capital Institute of Pediatrics, China

Brief Summary:

Asthma is the most common chronic respiratory disease in children and has much effect on their life and study, which leads to huge economic burden and pressure to the whole families. Some children will develop into adult patients so that asthma can be the life-long vigorous trouble. In recent years, the prevalence rate of children asthma is increasingly going up worldwide. The prevalence rate in last 12 months reported in USA, United Kingdom, Australia, New Zealand was between 12% to 30%.

Center for Asthma Prevention and Education of Capital Institute of Pediatrics investigated the national asthma prevalence in 900 thousands children in 27 provinces and cities, which average rate was 0.11% to 2.03% in 1990. In 2000, we investigated it again in 31 provinces(43 cities) and the average national children asthma prevalence rate was 1.97%(0.25% to 4.63%) which was much higher than that in 1990.


Condition or disease
Asthma

Detailed Description:
  1. Objectives

    1. To investigate the national children(0-14 years old)asthma prevalence;
    2. To compare the prevalence rate between that in 1990 and 2000;
    3. To analyse the asthma manifestations including the ages, seasons, causes, trigger and hereditary factors and their impact on the asthma patients, families and society;
    4. To identify the risk factors by questionnaires in case-control research.
  2. Study Design / Clinical Plan

    1. The screening stage: to distinguish suspected asthma from the children age from 0 to 14 years old.
    2. To obtain identified asthma from the suspected asthma.
    3. To evaluate the prevalence and severe degree of 0 to 14-year-old children asthma and gain the main risk factors by case-control research.

Layout table for study information
Study Type : Observational
Actual Enrollment : 20000 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: To Investigate the Prevalence of Children Asthma in China and Compare With That of the Last 20 Years
Study Start Date : April 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Group/Cohort
Asthma children
children with asthma symptoms through screening
normal children
children without symptoms of asthma



Primary Outcome Measures :
  1. prevalence of asthma [ Time Frame: Apr 2013 ]

Secondary Outcome Measures :
  1. prevalence of allergic rhinitis [ Time Frame: Apr 2013 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
children age from 0 to 14 years in big cities in China
Criteria

Inclusion Criteria:

  • children age from 0 to 14 years

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319292


Sponsors and Collaborators
Capital Institute of Pediatrics, China
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Chair: YuZhi Chen, professor Capital Institute of Pediatrics, China
Layout table for additonal information
Responsible Party: Chen Yuzhi, Professor, Capital Institute of Pediatrics, China
ClinicalTrials.gov Identifier: NCT01319292    
Other Study ID Numbers: MISP38877
First Posted: March 21, 2011    Key Record Dates
Last Update Posted: August 4, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases